Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies
Authors:
- for the COSYCONET study groupFGfor the COSYCONET study group
- Margarethe E. WackerMWMargarethe E. Wacker
- Rudolf A. JörresRJRudolf A. Jörres
- Annika KarchAKAnnika Karch
- Armin KochAKArmin Koch
- Joachim HeinrichJHJoachim Heinrich
- Stefan KarraschSKStefan Karrasch
- Holger SchulzHSHolger Schulz
- Annette PetersAPAnnette Peters
- Sven GläserSGSven Gläser
- Ralf EwertRERalf Ewert
- Sebastian E. BaumeisterSBSebastian E. Baumeister
Open Access
- 12 July 2016
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 17 (1) , 81
Abstract
Health-related quality of life (HRQL) is an important patient-reported outcome measure used to describe the burden of chronic obstructive pulmonary disease (COPD) which is often accompanied by comorbid conditions. Data from 2275 participants in the COPD cohort COSYCONET and from 4505 lung-healthy control subjects from the population-based KORA and SHIP studies were pooled. Main outcomes were the five dimensions of the generic EQ-5D-3 L questionnaire and two EQ-5D index scores using a tariff based on valuations from the general population and an experience-based tariff. The association of COPD in GOLD grades 1–4 and of several comorbid conditions with the EQ-5D index scores was quantified by multiple linear regression models while adjusting for age, sex, education, body mass index (BMI), and smoking status. For all dimensions of the EQ-5D, the proportion of participants reporting problems was higher in the COPD group than in control subjects. COPD was associated with significant reductions in the EQ-5D index scores (-0.05 points for COPD grades 1/2, -0.09 for COPD grade 3, -0.18 for COPD grade 4 according to the preference-based utility tariff, all p < 0.0001). Adjusted mean index scores were 0.89 in control subjects and 0.85, 0.84, 0.81, and 0.72 in COPD grades 1-4 according to the preference-based utility tariff and 0.76, 0.71, 0.68, 0.64, and 0.58 for control subjects and COPD grades 1-4 for the experience-based tariff respectively. Comorbidities had additive negative effects on the index scores; the effect sizes for comorbidities were comparable to or smaller than the effects of COPD grade 3. No statistically significant interactions between COPD and comorbidities were observed. Score differences between COPD patients and control subjects were most pronounced in younger age groups. Compared with control subjects, the considerable reduction of HRQL in patients with COPD was mainly due to respiratory limitations, but observed comorbidities added linearly to this effect. Younger COPD patients showed a greater loss of HRQL and may therefore be in specific need of comprehensive disease management. NCT01245933Keywords
This publication has 39 references indexed in Scilit:
- Comorbidities and Burden of COPD: A Population Based Case-Control StudyPLOS ONE, 2013
- Smoking and health-related quality of life in English general population: implications for economic evaluationsBMC Public Health, 2012
- An Official American Thoracic Society Workshop Report: The Integrated Care of the COPD PatientProceedings of the American Thoracic Society, 2012
- Utility Estimation in Chronic Obstructive Pulmonary DiseasePharmacoEconomics, 2011
- A Value Set for the EQ-5D Based on Experienced Health StatesPharmacoEconomics, 2011
- Cohort Profile: The Study of Health in PomeraniaInternational Journal of Epidemiology, 2010
- Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQHealth and Quality of Life Outcomes, 2010
- The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of EnglandQuality of Life Research, 2009
- Utilities of the EQ-5DPharmacoEconomics, 2009
- Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax, 2004